New Hudson Institute Director and CEO announced

By Hudson Institute communications

We are pleased to announce that Professor Elizabeth Hartland has accepted a position as the new Director and CEO of Hudson Institute of Medical Research. Professor Hartland obtained her BSc (Hons) majoring in Microbiology and Biochemistry and subsequently her PhD in Microbiology from the University of Melbourne.

Professor Elizabeth Hartland accepts a position as the new Director and CEO of Hudson Institute of Medical Research
Professor Elizabeth Hartland

She has held a Royal Society/NHMRC Howard Florey Fellowship at Imperial College London, academic positions in the Department of Microbiology, Monash University and an Australian Research Council Future Fellowship at the University of Melbourne.

Her leadership positions at Melbourne University include Chair of the Department of Microbiology and Deputy Director Peter Doherty Institute for Infection and Immunity. She is currently Acting Pro-Vice Chancellor Research Partnerships and External Relations, University of Melbourne.

Professor Hartland has a long-standing research interest in the pathogenesis of infections caused by E. coli and Legionella, with a focus on mechanisms of bacterial colonization and immune evasion.

Professor Hartland assumes the position from Professor Bryan Williams. Professor Williams has led the Institute since 2006, when he was appointed Director of Monash Institute of Medical Research (MIMR), and continued in this role through the merger process of MIMR with Prince Henry’s Institute, which resulted in the formation of Hudson Institute in 2014.

Professor Hartland will commence as Director and CEO in August 2017.

Contact us

Hudson Institute communications
t: +61 3 8572 2697

About Hudson Institute

Hudson Institute’ s research programs deliver in five areas of medical need – inflammation, cancer, reproductive health, newborn health, and hormones and health. More

Hudson News

Get the inside view on discoveries and patient stories

“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”

Alana Chantry